BRIEF-Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In Phase 2 Social Anxiety Disorder Prevail Study
BRIEF-Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In Phase 2 Social Anxiety Disorder Prevail Study
Brief-Bionomics獲得FDA批准在第二階段社交焦慮障礙流行研究中評估BNC210的IND
Nov 1 (Reuters) - Bionomics Ltd BNO.AX :
路透11月1日電-Bionomics Ltd BNO.AX:
* RECEIVES FDA CLEARANCE OF IND FOR EVALUATION OF BNC210 IN A PHASE 2 SOCIAL ANXIETY DISORDER PREVAIL STUDY
*獲得FDA批准在社交焦慮症流行研究中評估BNC210的IND
Source text for Eikon: ID:nASX50fDqk Further company coverage: BNO.AX
Eikon的源文本:ID:nASX50fDqk進一步的公司報道:BNO.AX
((Reuters.Briefs@thomsonreuters.com;))
(Reurs.Briefs@thomsonreurs.com;)